Hostname: page-component-89b8bd64d-46n74 Total loading time: 0 Render date: 2026-05-10T07:56:43.037Z Has data issue: false hasContentIssue false
  • English
  • Français

Economic Evaluation of Standing Order Programs for Pneumococcal Vaccination of Hospitalized Elderly Patients

Published online by Cambridge University Press:  02 January 2015

Donald B. Middleton ,
Chyongchiou J. Lin ,
Kenneth J. Smith ,
Richard K. Zimmerman ,
Mary Patricia Nowalk ,
Mark S. Roberts  and
Dwight E. Fox
Donald B. Middleton
Affiliation:
Departments of Family Medicine and Clinical Epidemiology, University of Pittsburgh School of Medicine, Pennsylvania
Chyongchiou J. Lin*
Affiliation:
Departments of Family Medicine and Clinical Epidemiology, University of Pittsburgh School of Medicine, Pennsylvania Radiation Oncology, University of Pittsburgh School of Medicine, Pennsylvania Departments of Behavioral and Community Health Sciences, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
Kenneth J. Smith
Affiliation:
Medicine, University of Pittsburgh School of Medicine, Pennsylvania
Richard K. Zimmerman
Affiliation:
Departments of Family Medicine and Clinical Epidemiology, University of Pittsburgh School of Medicine, Pennsylvania Departments of Behavioral and Community Health Sciences, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
Mary Patricia Nowalk
Affiliation:
Departments of Family Medicine and Clinical Epidemiology, University of Pittsburgh School of Medicine, Pennsylvania
Mark S. Roberts
Affiliation:
Medicine, University of Pittsburgh School of Medicine, Pennsylvania Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
Dwight E. Fox
Affiliation:
Departments of Family Medicine and Clinical Epidemiology, University of Pittsburgh School of Medicine, Pennsylvania
*
Department of Radiation Oncology, University of Pittsburgh School of Medicine, 535 UPMC Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, (cjlin@pitt.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

Background.

Standing order programs (SOPs), which allow for vaccination without an individual physician order, are the most effective mechanism to achieve high vaccination rates. Among the suggested settings for the utilization of SOPs are hospital inpatient units, because they provide care for those most likely to benefit from vaccination. The cost-effectiveness of this approach for elderly hospitalized persons is unknown. The purpose of this study was to estimate the cost-effectiveness of SOPs for pneumococcal polysaccharide vaccine (PPV) vaccination for patients 65 years of age or older in 2 types of hospital.

Methods.

In 2004, a 1,094-bed tertiary care hospital implemented a pharmacy-based SOP for PPV, and a 225-bed community hospital implemented a nursing-based SOP for PPV. Newly admitted patients 65 years of age or older were screened for PPV eligibility and then offered PPV. Vaccination rates before and after initiation of SOPs in the United States, incidence rates of invasive pneumococcal disease in the United States, and US economic data were the bases of the cost-effectiveness analyses. One-way and multivariate sensitivity analyses were conducted.

Results.

PPV vaccination rates increased 30.5% in the tertiary care hospital and 15.3% in the community hospital. In the base-case cost-effectiveness analysis, using a societal perspective, we found that both pharmacy-based and nursing-based SOPs cost less than $10,000 per quality-adjusted life-year gained, with program costs (pharmacy-based SOPs cost $4.16 per patient screened, and nursing-based SOPs cost $4.60 per patient screened) and vaccine costs ($18.33 per dose) partially offset by potential savings from cases of invasive pneumococcal disease avoided ($12,436 per case). Sensitivity analyses showed SOPs for PPV vaccination to be cost-effective, compared with PPV vaccination without SOPs, unless the improvement in vaccination rate was less than 8%.

Conclusion.

SOPs do increase PPV vaccination rates in hospitalized elderly patients and are economically favorable, compared with PPV vaccination rates without SOPs.

Information

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 29 , Issue 5 , May 2008 , pp. 385 - 394
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46:1–24.Google Scholar
2.Rubins, JB, Janoff, EN. Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs Aging 2001;18:305–311.CrossRefGoogle ScholarPubMed
3.Butler, JC, Breiman, RF, Campbell, JF, Lipman, HB, Broome, CV, Facklam, RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826–1831.Google Scholar
4.Sisk, JE, Whang, W, Butler, JC, Sneller, VP, Whitney, CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138:960–968.CrossRefGoogle ScholarPubMed
5.Centers for Disease Control and Prevention—National Center for Health Statistics. NCHS-NHIS data from the January-September 2005 National Health Interview Survey. 2006. Available at: http://www.cdc.gov/nchs/about/major/nhis/released200603.htm#4. Accessed September 30, 2007.Google Scholar
6.US Department of Health and Human Services. Healthy People 2010 Vol. 1: Understanding and Improving Health and Vol. 2: Objectives for Improving Health. 2nd ed. Washington, DC: US Government Printing Office; 2000.Google Scholar
7.Moore, RA, Wiffen, PJ, Lipsky, BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Family Practice 2000;1:1.CrossRefGoogle ScholarPubMed
8.Fisman, DN, Abrutyn, E, Spaude, KA, Kim, A, Kirchner, C, Daley, J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006;42:1093–1101.CrossRefGoogle ScholarPubMed
9.Fedson, DS. Hospital-based pneumococcal immunization: the epidemiologic rationale and its implementation. Infect Control 1982;3:303–308.CrossRefGoogle ScholarPubMed
10.Shapiro, ED, Berg, AT, Austrian, R, et, al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453–1460.Google Scholar
11.McKibben, LJ, Stange, PV, Sneller, VP, Strikas, RA, Rodewald, LE, Advisory Committee on Immunization Practices. Use of standing orders programs to increase adult vaccination rates. MMWR Recomm Rep 2000;49:15–16.Google ScholarPubMed
12.Dexter, PR, Perkins, SM, Maharry, KS, Jones, K, McDonald, CJ. Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates. JAMA 2004;292:2366–2371.CrossRefGoogle ScholarPubMed
13.Shefer, A, McKibben, L, Bardenheier, B, Bratzier, D, Roberts, H. Characteristics of long-term care facilities with standing order programs to deliver influenza and pneumococcal vaccinations to residents in 13 states. J Am Med Dir Assoc 2005;6:97–104.CrossRefGoogle ScholarPubMed
14.Bakare, M, Shrivastava, R, Jeevanantham, V, Navaneethan, SD. Impact of two different models on influenza and pneumococcal vaccination in hospitalized patients. South Med J 2007;100:140–144.CrossRefGoogle ScholarPubMed
15.Honeycutt, AA, Coleman, MS, Anderson, WL, Wirth, KE. Cost-effectiveness of hospital vaccination programs in North Carolina. Vaccine 2007;25:1484–1496.CrossRefGoogle ScholarPubMed
16.Sisk, J, Moskowitz, AJ, Whang, W, et al.Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people [published correction appears in JAMA 2000;283:341]. JAMA 1997;278:1333–1339.Google Scholar
17.Centers for Medicare and Medicaid Series H. Medicare and Medicaid programs; conditions of participation: immunization standards for hospitals, long-term care facilities, and home health agencies: final rule with comment period. Fed Reg 2002;67:61808–61814.Google Scholar
18.Nowalk, MP, Middleton, DB, Zimmerman, RK, Hess, MM, Skledar, SJ, Jacobs, MA. Increasing pneumococcal vaccination rates among hospitalized patients. Infect Control Hosp Epidemiol 2003;24:526–531.CrossRefGoogle ScholarPubMed
19.Skledar, SJ, Hess, MM, Ervin, KA, et al.Designing a hospital-based pneumococcal vaccination program. Am J Health Syst Pharm 2003;60:1471–1476.CrossRefGoogle ScholarPubMed
20.Centers for Disease Control and Prevention. Self-reported pneumococcal vaccination coverage trends 1989-2005 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States, National Health Interview Survey (NHIS). Available at: http://www.cdc.gov/flu/professionals/vaccination/pdf/pneumococcal-vaccinetrend.pdf. Accessed September 30, 2007.Google Scholar
21.Husain, S, Slobodkin, D, Weinstein, RA. Pneumococcal vaccination: analysis of opportunities in an inner-city hospital. Arch Intern Med 2002;162:1961–1965.CrossRefGoogle Scholar
22.Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage among persons aged > or = 65 years— United States, 2004-2005. MMWR Morb Mortal Wkly Rep 2006;55:1065–1068.+or+=+65+years—+United+States,+2004-2005.+MMWR+Morb+Mortal+Wkly+Rep2006;55:1065–1068.>Google Scholar
23.Agency for Healthcare Research and Quality. Healthcare Cost & Utilization Project (HCUP). 2003. Available at: http://www.ahrq.gov/data/hcup/. Accessed September 30, 2007.Google Scholar
24.Lexau, CA, Lynfield, R, Danila, R, et al.Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005;294:2043–2051.Google Scholar
25.Weaver, M, Krieger, J, Castorina, J, Walls, M, Ciske, S. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Intern Med 2001;161:111–120.Google Scholar
26.Robinson, KA, Baughman, W, Rothrock, G, et al.Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001;285:1729–1735.CrossRefGoogle ScholarPubMed
27.Gold, M, Siegel, J, Russell, L, Weinstein, M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.CrossRefGoogle ScholarPubMed
28.HCUP-US Cost-to-Charge Ratio Files. Healthcare Cost and Utilization Project (HCUP). 2007. Available at: http://www.hcup-us.ahrq.gov/db/state/costtocharge.jsp. Accessed September 30, 2007.Google Scholar
29.Erickson, P, Wilson, R, Shannon, I. Years of healthy life. Statistical Note No 7, National Center for Health Statistics. 1995;7:1–14.Google Scholar
30.Drummond, MF, O'Brien, B, Stoddart, GL, Torrance, GW. Methods for the Economic Evaluation of Health Care Programs. 2nd ed. New York: Oxford University Press; 1997.Google Scholar
31.Sisk, JE, Whang, W, Butler, JC, Sneller, VP, Whitney, CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003;138:960–968.Google Scholar
32.Jackson, LA, Benson, P, Sneller, VP, et al.Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243–248.Google Scholar
33.Laupacis, A, Feeny, D, Detsky, AS, Tugwell, PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473–481.Google ScholarPubMed
34.Mullooly, JP, Bennett, MD, Hornbrook, MC, et al.Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994;121:947–952.CrossRefGoogle Scholar
35.Nichol, KL, Margolis, KL, Wuorenma, J, Von Sternberg, TL. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778–784.Google Scholar
36.Rothberg, MB, Virapongse, A, Smith, KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007;44:1280–1288.Google Scholar
37.Hornberger, J, Robertus, K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006;145:317–325.Google Scholar
38.Centers for Disease Control and Prevention. Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation. MMWR Morbid Mortal Wkly Rep 2000;49(RR-01):1–13.Google Scholar
39.Middleton, DB, Fox, DE, Nowalk, MP, et al.Overcoming barriers to establishing an inpatient vaccination program for pneumococcus using standing orders. Infect Control Hosp Epidemiol 2005;26:874–881.CrossRefGoogle ScholarPubMed
40.Goldstein, AO, Kincade, JE, Resnick, JE, Gamble, G, Bearman, RS. Policies to increase influenza and pneumococcal immunizations in chronically ill and institutionalized settings. Am J Infect Control 2005;33:463–468.CrossRefGoogle ScholarPubMed
41.Sokos, D, Skledar, S, Ervin, K, et al.Designing and implementing a hospital-based vaccine standing orders program. Am J Health Syst Pharm 2007;64:1096–1102.Google Scholar
42.Lindley, M, Shefer, A, and Shaw, F. Assessing state immunization requirements for healthcare workers and patients. In: Program and abstracts of the 40th National Immunization Conference; 2006; Atlanta, GA.Google Scholar
43.Hicks, LA, Harrison, LH, Flannery, B, et al.Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine PCV7 serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196:1346–1354.Google Scholar
44.Simberkoff, MS, Cross, AP, Al-Ibrahim, M, et al.Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;315:1318–1327.CrossRefGoogle ScholarPubMed
45.Fedson, DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness. Semin Res-pir Infect 1993;8:285–293.Google Scholar
46.Sisk, JE, Riegelman, RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986;104:79–86.Google Scholar
47.Gable, CB, Holzer, SS, Engelhart, L, et al.Pneumococcal vaccine: efficacy and associated cost savings. JAMA 1990;264:2910–2915.Google Scholar
48.Patrick, KM, Woolley, FR. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981;245:473–477.CrossRefGoogle ScholarPubMed
49.Willems, JS, Sanders, CR, Riddiough, MA, Bell, JC. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980;303:553–559.CrossRefGoogle ScholarPubMed
50.DeGraeve, D, Beutels, P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics 2004;22:719–740.Google Scholar
51.DeGraeve, D, Lombaert, G, Goossens, H. Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium. Pharmacoeconomics 2000;17:591–601.Google Scholar
52.Jackson, LA, Neuzil, KM, Yu, O, et al.Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003;348:1747–1755.Google Scholar
53.Fine, MJ, Smith, MA, Carson, CA, et al.Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666–2677.CrossRefGoogle ScholarPubMed
54.Walker, FJ, Singleton, RJ, Bulkow, LR, Strikas, RA, Butler, JC. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis 2005;40:1730–1735.CrossRefGoogle ScholarPubMed